Valuation: Egetis Therapeutics AB

Market Cap 3.25B 343M 297M 277M 253M 477M 32.67B 485M 1.28B 16.34B 1.29B 1.26B 54.43B P/E 2026 *
476x
P/E 2027 * -21.2x
Enterprise Value 2.76B 291M 252M 235M 215M 405M 27.72B 411M 1.08B 13.87B 1.09B 1.07B 46.19B EV / Sales 2026 *
6.28x
EV / Sales 2027 * 8.27x
Free-Float
40.16%
Yield 2026 *
-
Yield 2027 * -
1 day-1.27%
1 week+14.40%
Current month+16.50%
1 month+14.97%
3 months+7.87%
6 months+35.20%
Current year+30.90%
1 week 6.39
Extreme 6.39
7.21
1 month 5.86
Extreme 5.86
7.21
Current year 4.23
Extreme 4.23
7.21
1 year 3.62
Extreme 3.625
7.21
3 years 3.02
Extreme 3.025
9.3
5 years 3
Extreme 3.005
9.3
10 years 3
Extreme 3.005
50.75
Manager TitleAgeSince
Chief Executive Officer 50 2017-06-15
Director of Finance/CFO 47 2017-12-30
Chief Tech/Sci/R&D Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 65 2016-12-31
Director/Board Member 65 2016-12-31
Chairman 61 2024-05-05
Date Insider Type Main position Quantity % Market Cap.
5/13/26 Sell

Chief Executive Officer

-286,071 0.0724%
5/11/26 Fiscal year

Chief Financial Officer

264,880 0.0670%
1/16/26 Buy

Chairman

150,000 0.0380%
Change 5-day change 1-year change 3-year change Capi.($)
-1.27%+14.40%+20.93%+57.79% 343M
+4.21%+25.56%+77.96%+104.49% 70.85B
+0.50%+6.20%+34.94%+67.83% 55.41B
+2.78%+36.87%+23.00%+493.09% 29.43B
+1.78%+18.87%+57.08%+5.18% 24.12B
-0.93%+0.60%-16.89%-12.00% 23.31B
-0.35%+7.91%+44.14%-22.61% 18.37B
+0.85%+10.84%+31.14%+628.97% 16.1B
+7.26%+14.16%+221.03%+393.89% 16.99B
-2.05%-3.81%+40.40%+150.40% 13.12B
Average +0.87%+10.09%+53.37%+186.70% 26.81B
Weighted average by Cap. +1.70%+11.59%+54.93%+163.83%

Financials

2026 *2027 *
Net sales 439M 46.24M 40.03M 37.42M 34.2M 64.44M 4.41B 65.45M 172M 2.21B 174M 170M 7.35B 353M 37.17M 32.18M 30.08M 27.49M 51.81M 3.55B 52.62M 138M 1.77B 140M 137M 5.91B
Net income 302M 31.87M 27.59M 25.79M 23.57M 44.41M 3.04B 45.11M 119M 1.52B 120M 117M 5.06B -95.62M -10.08M -8.72M -8.15M -7.45M -14.04M -961M -14.26M -37.52M -481M -37.84M -37.01M -1.6B
Net Debt -492M -51.88M -44.91M -41.98M -38.36M -72.29M -4.95B -73.42M -193M -2.48B -195M -191M -8.24B -334M -35.21M -30.48M -28.49M -26.04M -49.06M -3.36B -49.83M -131M -1.68B -132M -129M -5.59B
Logo Egetis Therapeutics AB
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Employees
44
Date Price Change Volume
26-08-10 SEK 6.990 -1.27% 1,121,387
26-08-07 SEK 7.080 +3.36% 1,256,588
26-08-06 SEK 6.850 +1.63% 731,610
26-08-05 SEK 6.740 +5.64% 803,369
26-08-04 SEK 6.380 +4.42% 844,845
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
6.990SEK
Average target price
15.33SEK
Spread / Average Target
+119.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EGTX Stock